论文部分内容阅读
Woods LK等:The Lancet 1992;3 39(8809):1533～1558药理浓度镁的心血管作用包括扩张冠状动脉和体循环血管,抑制血小板聚集和抗心律失常。几项临床试验提示,可疑AMI(急性心肌梗塞)急性期输入镁盐可降低早期死亡率,但因样本太小,不足以做出肯定的结论。因此作者设计实施了该实验,以验证以下假设:(1)静脉用镁降低可疑AMI病人早期死亡率:(2)镁可阻止不稳定心绞痛发展成AMI;(3)降低可疑AMI病人临床上重要的早期心律失常发生率。 1 方法 于1987年～1992年2月在Keicester皇家医院CCU中进行了本试验。若病人被判定可能在24小时内发生AMI,则纳入本研究。诊断AMI的标准至不符合下述两条:典型的病史;血清肌酸肌酶升高至少2倍于正常上限,并有羟丁酸脱氢酶升高支持;与MI有关的心电图动态演变。下列病人被排除:(1)不能或拒绝给予口头上的同意;(2)完全心脏阻滞;(3)已参加其他试验;(4)有使用镁治疗的临床适应症;(5)
Woods LK, et al .: The Lancet 1992; 3 39 (8809): 1533-1558 Pharmacological Concentrations Cardiovascular effects of magnesium include the expansion of coronary arteries and systemic blood vessels, inhibition of platelet aggregation and antiarrhythmias. Several clinical trials suggest that the acute phase of suspected AMI (acute myocardial infarction) may reduce the early mortality rate of magnesium, but the sample is too small, not enough to make a positive conclusion. The authors therefore designed and implemented the experiment to verify the following assumptions: (1) intravenous magnesium to reduce early mortality in patients with suspected AMI: (2) magnesium can prevent the development of unstable angina to AMI; (3) reduce the clinically important suspicious AMI patients The incidence of early arrhythmia. 1 Method The trial was conducted at Keicester Royal Hospital CCU from 1987 to February 1992. Patients were included in the study if they were judged to have AMI within 24 hours. The criteria for diagnosing AMI do not meet the following two criteria: a typical medical history; elevated serum creatine kinase at least 2-fold above normal upper limit with elevated support for oxybutyrate dehydrogenase; and electrocardiographic dynamics associated with MI. The following patients were excluded: (1) can not or refused to give verbal consent; (2) complete heart block; (3) have participated in other tests; (4) have clinical indications for treatment with magnesium; (5)